2. Search Result
Search Result
Results for "

Acute myeloid leukaemia

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

4

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-134836
    STM2457
    100+ Cited Publications

    		 Apoptosis METTL3 Cancer
    STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) .
    STM2457
  • HY-108894
    Ferumoxytol

    		Ferroptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    Ferumoxytol is an FDA-approved ultrasmall superparamagnetic iron oxide preparation and iron replacement agent that exerts selective activity against leukemia cells with low ferroportin expression. Ferumoxytol increases intracellular iron levels, induces reactive oxygen species (ROS) production via the Fenton reaction, and triggers oxidative stress and cell death. Ferumoxytol reduces disease burden in mouse models and patient-derived leukemia models. As an MRI contrast agent, Ferumoxytol enables imaging of vascular lesions, tumors and lymph nodes. Ferumoxytol can be used in research related to acute myeloid leukemia and blast-phase chronic myeloid leukemia .
    Ferumoxytol
  • HY-157334
    DEG-77
    1 Publications Verification

    		 Molecular Glues Casein Kinase IKZF Family Bcl-2 Family CDK Apoptosis Cancer
    DEG-77 is a molecular glue targeting IKZF2 and CK1α, with DC50 values of 15.3 nM and 10 nM, respectively. DEG-77 exhibits significant anti-tumor activity, inducing increased transcriptional levels of the pro-apoptotic protein Bax and the cell cycle arrest protein p21. DEG-77 is applicable to the research of acute myeloid leukemia (AmL), diffuse large B-cell lymphoma and ovarian cancer.
    DEG-77
  • HY-P99390
    Tepoditamab

    MCLA 117

    		 CD3 Interleukin Related IFNAR TNF Receptor Inflammation/Immunology Cancer
    Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
    Tepoditamab
  • HY-122623A
    DB818 dihydrochloride

    		Apoptosis Cancer
    DB818 dihydrochloride is the dihydrochloride salt form of DB818 (HY-122623). DB818 dihydrochloride is an inhibitor for Homeobox A9 (HOXA9). DB818 dihydrochloride reduces the formation of HOXA9-DNA complexes, inhibits the growth and induces apoptosis in AML cell lines OCI/AML3, MV4-11, and THP-1 .
    DB818 dihydrochloride
  • HY-P991247
    Anti-HLA-A2 (Hu8F4)

    		MHC Cancer
    Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-HLA-A2 (Hu8F4)
  • HY-10226
    JNJ-16241199

    R306465

    		 Apoptosis HDAC Cancer
    JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199
  • HY-P991560
    TQB-2928

    		CD47 Cancer
    TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.
    TQB-2928
  • HY-149030
    DHODH-IN-21

    		Dihydroorotate Dehydrogenase Cancer
    DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML) .
    DHODH-IN-21
  • HY-150586
    PTG-0861

    		HDAC Apoptosis Cancer
    PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC50 value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers .
    PTG-0861
  • HY-P991425
    AT-1413

    		Transmembrane Glycoprotein Cancer
    AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    AT-1413
  • HY-N10079
    Suchilactone

    Jatrophan

    		 SHP2 Cancer
    Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML) .
    Suchilactone
  • HY-150562
    CDK9-IN-19

    		CDK Cancer
    CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC50 value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .
    CDK9-IN-19
  • HY-182766
    AMX-883

    		Molecular Glues Epigenetic Reader Domain Cancer
    AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML) .
    AMX-883
  • HY-10226R
    JNJ-16241199 (Standard)

    R306465 (Standard)

    		 Reference Standards Apoptosis HDAC Cancer
    JNJ-16241199 (Standard) is the analytical standard of JNJ-16241199 (HY-10226). This product is intended for research and analytical applications. JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199 (Standard)
  • HY-138195
    NEO212

    		DNA/RNA Synthesis Apoptosis FAK Src MMP Autophagy Cancer
    NEO212 is an orally active, blood-brain barrier permeable conjugate of Temozolomide (TMZ) (HY-17364) and Perillyl Alcohol (POH) (HY-N7000), with potent anticancer activity. NEO212 overcomes classical TMZ resistance and DNA alkylation by depleting MGMT. By inhibiting the FAK/Src signaling pathway, NEO212 reduces the production of MMP2 and MMP9, induces mesenchymal-epithelial transition, and inhibits the migration, invasion and tumor progression of glioma stem cells. NEO212 disrupts autophagy flux to enhance mitochondrial apoptosis; it induces differentiation of acute myeloid leukemia (AML) cells into macrophages and proliferation arrest .
    NEO212

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: